Paget disease of bone: Therapeutic options

Journal of Clinical Rheumatology

Volumn 14, Issue 5, 2008, Pages 299-305

  Silverman, Stuart L ^a,b  

^a OMC Clinical Research Center   (United States)

^b Cedars Sinai/UCLA   (United States)

Author keywords

Bisphosphonates; Osteoclasts; Paget disease; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DACTINOMYCIN; ETIDRONIC ACID; GALLIUM NITRATE; GLUCAGON DERIVATIVE; MITHRAMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLPADRONIC ACID; OPIATE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D; ZOLEDRONIC ACID; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE;

ABDOMINAL PAIN; ACUPUNCTURE; BACKACHE; BONE BIOPSY; BONE PAIN; BONE SCINTISCANNING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEARTBURN; HUMAN; HYDROTHERAPY; HYPOCALCEMIA; IRITIS; JOINT PROSTHESIS; LABORATORY TEST; LOW BACK PAIN; LOW DRUG DOSE; MORNING DOSAGE; NAUSEA; NERVE ROOT COMPRESSION; NERVE STIMULATION; NEUROLOGIC DISEASE; OSTEOARTHRITIS; PAGET BONE DISEASE; PRIORITY JOURNAL; RADICULOPATHY; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; WALKING AID; X RAY; BLOOD; RETREATMENT; TREATMENT OUTCOME;

ALENDRONATE; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; HUMANS; OSTEITIS DEFORMANS; RETREATMENT; TREATMENT OUTCOME;

EID: 58949096155     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318188b1f3     Document Type: Review

References (43)

1. Lyles KW, Siris ES, Singer FR, et al. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res. 2001; 16:1379-1387.
2. Altman RD. Paget's disease of bone. In: Coe FL, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:985-1020.
3. Woodard HQ. Long term studies of the blood chemistry in Paget's disease of bone. Cancer. 1959;12:1226-1237.
4. Alvarez L, Guañabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res. 1995;10:458-465.
5. Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J Bone Miner Res. In press.
6. Rousiere M, Michou L, Cornélis F, et al. Paget's disease of bone. Best Pract Res Clin Rheumatol. 2003;17:1019-1041.
7. Briesacher BA, Orwig D, Seton M, et al. Medical care costs of Paget's disease of bone in a privately insured population. Bone. 2006;38: 731-737.
8. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med. 1996;101:341-348.
9. Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum. 1992;35: 967-974.
10. Langston AL, Ralston SH. Management of Paget's disease of bone. Rheumatology. 2004;43:955-959.
11. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer. 1997;75:295-300.
12. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353:898-908.
13. Selby PL, Davie MWJ, Ralston SH, et al. Guidelines on the management of Paget's disease of bone. Bone. 2002;31:366-373.
14. Hosking DJ. Advances in the management of Paget's disease of bone. Drugs. 1990;40:829-840.
15. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphospho-nates. J Pharmacol Exp Ther. 2001;296:235-242.
16. Frith JC, Mönkkönen J, Auriola S, et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001;44:2201-2210.
17. Kelly R, Taggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ. 1997;315:1235.
18. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021.
19. Joshua F, Epstein M, Major G. Bisphosphonate resistance in Paget's disease. Bone. 2004;27(suppl 4):S24.
20. Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab. 1977;44:96-106.
21. Russell RG, Smith R, Preston C, et al. Diphosphonates in Paget's disease. Lancet. 1974;1:894-898.
22. Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000. Clin Ther. 2001;23:620-626.
23. Khairi MRA, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Ann Intern Med. 1977;87:656-663.
24. Boyce BF, Smith L, Fogelman I, et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984;1: 821-824.
25. Gibbs CJ, Aaron JE, Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J (Clin Res Ed). 1986;292:1227-1229.
26. Siris ES. Goals of treatment for Paget's disease of bone. J Bone Miner Res. 1999;14(suppl 2):49-52.
27. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1995; 38:851-858.
28. Rendina D, Mossetti G, Viceconti R, et al. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int. 2004;75:189-196.
29. Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J Bone Miner Res. 1993;8:1467-1473.
30. Selby PL. Pamidronate in the treatment of Paget's disease. Bone. 1999;24(suppl):S57-S58.
31. Trombetti A, Arlot M, Thevenon J, et al. Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed. 1999;66:467-476.
32. Gutteridge DH, Ward LC, Stewart GO, et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res. 1999;14(suppl 2):79-84.
33. Stewart GO, Stuckey BG, Ward LC, et al. Iritis following intravenous pamidronate. Aust N Z J Med. 1996;26:414-415.
34. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med. 1996;171:341-348.
35. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81:961-967.
36. Miller PD, Brown JP, Siris ES, et al; Paget's Risedronate/Etidronate Study Group. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med. 1999;106:513-520.
37. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13:1032-1038.
38. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617-627.
39. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22:142-148.
40. Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone. 2006;39:954-958.
41. Reclast [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
42. Eastell R. Biochemical markers of bone turnover in Paget's disease of bone. Bone. 1999;24(suppl):S49-S50.
43. Actonel [package insert]. 2007. Cincinnati, Ohio: Procter & Gamble Pharmaceuticals; 2006.